全文获取类型
收费全文 | 1324754篇 |
免费 | 101936篇 |
国内免费 | 4219篇 |
专业分类
耳鼻咽喉 | 16782篇 |
儿科学 | 43458篇 |
妇产科学 | 36355篇 |
基础医学 | 196197篇 |
口腔科学 | 35872篇 |
临床医学 | 128813篇 |
内科学 | 255513篇 |
皮肤病学 | 26349篇 |
神经病学 | 110970篇 |
特种医学 | 48111篇 |
外国民族医学 | 366篇 |
外科学 | 183480篇 |
综合类 | 28737篇 |
现状与发展 | 1篇 |
一般理论 | 460篇 |
预防医学 | 113300篇 |
眼科学 | 28908篇 |
药学 | 98543篇 |
6篇 | |
中国医学 | 3097篇 |
肿瘤学 | 75591篇 |
出版年
2019年 | 11627篇 |
2018年 | 16304篇 |
2017年 | 12282篇 |
2016年 | 13248篇 |
2015年 | 15195篇 |
2014年 | 20797篇 |
2013年 | 32048篇 |
2012年 | 44242篇 |
2011年 | 46889篇 |
2010年 | 27078篇 |
2009年 | 24930篇 |
2008年 | 42715篇 |
2007年 | 45055篇 |
2006年 | 45166篇 |
2005年 | 43597篇 |
2004年 | 41551篇 |
2003年 | 39407篇 |
2002年 | 38219篇 |
2001年 | 60721篇 |
2000年 | 62347篇 |
1999年 | 51916篇 |
1998年 | 13683篇 |
1997年 | 12259篇 |
1996年 | 12159篇 |
1995年 | 12354篇 |
1994年 | 11567篇 |
1993年 | 10827篇 |
1992年 | 41479篇 |
1991年 | 40739篇 |
1990年 | 39422篇 |
1989年 | 37312篇 |
1988年 | 34541篇 |
1987年 | 33667篇 |
1986年 | 32118篇 |
1985年 | 30619篇 |
1984年 | 22990篇 |
1983年 | 19524篇 |
1982年 | 11690篇 |
1981年 | 10221篇 |
1979年 | 20759篇 |
1978年 | 14769篇 |
1977年 | 12014篇 |
1976年 | 11833篇 |
1975年 | 12081篇 |
1974年 | 14774篇 |
1973年 | 14452篇 |
1972年 | 13349篇 |
1971年 | 12408篇 |
1970年 | 11472篇 |
1969年 | 10402篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Sophia Ahmed Hussen Meron Gurji Argaw Mulugeta Tsegaye Karen L. Andes Danielle Gilliard Carlos del Rio 《Culture, health & sexuality》2019,21(4):447-461
Historically, Ethiopian women have faced numerous challenges to gender equity at the individual, relational and community levels; such inequalities can lead to increased risk of HIV acquisition. Over the past two decades, some progress has been made towards changing policies and norms to reduce gender inequality. We sought to understand the ways in which marriage and other romantic/sexual relationships of a group of Ethiopian women living with HIV had been impacted by gender norms, relational power dynamics and HIV status over the life course. We conducted in-depth interviews with 19 women living with HIV who were working as peer educators at a large clinic in Addis Ababa, Ethiopia. Reflecting on their early lives, participants often described traumatic prior relationships characterised by rape, forced marriage and HIV nondisclosure. In the aftermath of being diagnosed with HIV, participants’ more recent relationships embodied a more egalitarian dynamic characterised by mutual support for HIV care engagement and open communication. Participants’ narratives illustrate encouraging examples of ways in which HIV-positive women can form and maintain equitable and satisfying personal relationships even in the context of obstacles at multiple levels. 相似文献
102.
Miriam L. Haaksma Debora Rizzuto Inez H.G.B. Ramakers Sara Garcia-Ptacek Alessandra Marengoni Wiesje M. van der Flier Frans R.J. Verhey Marcel G.M. Olde Rikkert René J.F. Melis 《Journal of the American Medical Directors Association》2019,20(2):165-170.e2
Objectives
The predictive value of frailty and comorbidity, in addition to more readily available information, is not widely studied. We determined the incremental predictive value of frailty and comorbidity for mortality and institutionalization across both short and long prediction periods in persons with dementia.Design
Longitudinal clinical cohort study with a follow-up of institutionalization and mortality occurrence across 7 years after baseline.Setting and Participants
331 newly diagnosed dementia patients, originating from 3 Alzheimer centers (Amsterdam, Maastricht, and Nijmegen) in the Netherlands, contributed to the Clinical Course of Cognition and Comorbidity (4C) Study.Measures
We measured comorbidity burden using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) and constructed a Frailty Index (FI) based on 35 items. Time-to-death and time-to-institutionalization from dementia diagnosis onward were verified through linkage to the Dutch population registry.Results
After 7 years, 131 patients were institutionalized and 160 patients had died. Compared with a previously developed prediction model for survival in dementia, our Cox regression model showed a significant improvement in model concordance (U) after the addition of baseline CIRS-G or FI when examining mortality across 3 years (FI: U = 0.178, P = .005, CIRS-G: U = 0.180, P = .012), but not for mortality across 6 years (FI: U = 0.068, P = .176, CIRS-G: U = 0.084, P = .119). In a competing risk regression model for time-to-institutionalization, baseline CIRS-G and FI did not improve the prediction across any of the periods.Conclusions
Characteristics such as frailty and comorbidity change over time and therefore their predictive value is likely maximized in the short term. These results call for a shift in our approach to prognostic modeling for chronic diseases, focusing on yearly predictions rather than a single prediction across multiple years. Our findings underline the importance of considering possible fluctuations in predictors over time by performing regular longitudinal assessments in future studies as well as in clinical practice. 相似文献103.
104.
105.
Deepti Bettampadi Luisa L. Villa Eduardo L. Ponce Jorge Salmeron Bradley A. Sirak Martha Abrahamsen Julie A. Rathwell Richard R. Reich Anna R. Giuliano 《International journal of cancer. Journal international du cancer》2020,146(11):3026-3033
Incidence of human papillomavirus (HPV) attributable oropharyngeal cancers (OPCs) has been increasing globally, especially among men in high-income countries. There is a lack of studies comparing oral HPV prevalence by age and country among healthy men. The purpose of our study was to assess oral HPV prevalence by country and age. Participants of the HPV Infection in Men Study (HIM), a cohort of 3,098 healthy men from São Paulo, Brazil, Cuernavaca, Mexico and Tampa, USA, were studied. Oral HPV prevalence and type distribution were assessed using the SPF10 PCR-DEIA-LiPA25 system. The prevalence of any HPV in Brazil, Mexico and the US was 8.7% (95% CI: 7.1%, 10.4%), 10.0% (95% CI: 8.3%, 12.1%) and 7.6% (95% CI: 5.9%, 9.5%), respectively, while the prevalence of high-risk HPV was 5.3% (95% CI: 4.1%, 6.7%), 7.3% (95% CI: 5.7%, 9.0%) and 5.4% (95% CI: 4.0%, 7.0%), respectively. No significant differences in prevalence of grouped HPV types were observed by country despite significant differences in sexual behaviors. However, the age-specific prevalence of oral HPV differed by country. Brazilian (6.0% [95% CI: 3.4%, 9.7%]) and Mexican (9.2% [95% CI: 5.6%, 14.0%]) participants had peak high-risk HPV prevalence among men aged 41–50 years whereas the US participants had peak prevalence at ages 31–40 years (11.0% [95% CI: 6.4%, 17.3%]). In conclusion, oral HPV prevalence was low with no difference in overall prevalence observed by country. Factors associated with the differences in oral HPV age-patterning by country and sexual orientation require further study. 相似文献
106.
107.
108.
Mohamed E. Salem J. Nicholas Bodor Alberto Puccini Joanne Xiu Richard M. Goldberg Axel Grothey W. Michael Korn Anthony F. Shields William M Worrilow Edward S. Kim Heinz-Josef Lenz John L. Marshall Michael J. Hall 《International journal of cancer. Journal international du cancer》2020,147(10):2948-2956
Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in a diverse sample of tumors. Hypothesized differences were identified by the protein/gene affected/mutated and the tumor histology/primary site. Overall, 1057 MSI-H tumors were identified from the 32 932 tested. MSI was examined by NGS using 7000+ target microsatellite loci. TMB was calculated using only nonsynonymous missense mutations sequenced with a 592-gene panel; a subset of MSI-H tumors also had MMR IHC performed. Analyses examined TMB by MMR protein heterodimer impacted (loss of MLH1/PMS2 vs. MSH2/MSH6 expression) and gene-specific mutations. The sample was 54.6% female; mean age was 63.5 years. Among IHC tested tumors, loss of co-expression of MLH1/PMS2 was more common (n = 544/705, 77.2%) than loss of MSH2/MSH6 (n = 81/705, 11.5%; P < .0001), and was associated with lower mean TMB (MLH1/PMS2: 25.03 mut/Mb vs MSH2/MSH6 46.83 mut/Mb; P < .0001). TMB also varied by tumor histology: colorectal cancers demonstrating MLH1/PMS2 loss had higher TMBs (33.14 mut/Mb) than endometrial cancers (20.60 mut/Mb) and other tumors (25.59 mut/Mb; P < .0001). MMR gene mutations were detected in 42.0% of tumors; among these, MSH6 mutations were most common (25.7%). MSH6 mutation patterns showed variability by tumor histology and TMB. TMB varies by underlying cause(s) of MSI and tumor histology; this heterogeneity may contribute to differences in response to ICI. 相似文献
109.
Maria M. Rubinstein MD David M. Hyman MD Imogen Caird BA Helen Won MS Krysten Soldan BSN Kenneth Seier MS Alexia Iasonos PhD William P. Tew MD Roisin E. O’Cearbhaill MD Rachel N. Grisham MD Martee L. Hensley MD Tiffany Troso-Sandoval MD Paul Sabbatini MD Joyce Guillen BS S. Duygu Selcuklu PhD Catherine Zimel BS Jean Torrisi MD Carol Aghajanian MD Vicky Makker MD 《Cancer》2020,126(6):1274-1282
110.
Christopher L. Heidler Eva K. Roth Markus Thiemann Claudia Blattmann Ramon L. Perez Peter E. Huber Michal Kovac Beate Amthor Gabriele Neu-Yilik Andreas E. Kulozik 《International journal of cancer. Journal international du cancer》2020,147(4):1059-1070
Progress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediatric osteosarcoma. The checkpoint kinase (chk) inhibitor prexasertib (LY2606368) and its salt form (LSN2940930) have recently been shown to be active in adult and pediatric malignancies, including sarcoma. We have now tested the potency of prexasertib in clonogenic survival assays in two new lines of primary patient-derived osteosarcoma cells and in two established osteosarcoma cell lines as a single agent and in combination with cisplatin and the poly ADP-ribose polymerase (PARP) inhibitor talazoparib. Prexasertib alone results in strongly reduced clonogenic survival at low nanomolar concentrations and acts by affecting cell cycle progression, induction of apoptosis and induction of double-stranded DNA breakage at concentrations that are well below clinically tolerable and safe plasma concentrations. In combination with cisplatin and talazoparib, prexasertib acts in a synergistic fashion. Chk1 inhibition by prexasertib and its combination with the DNA damaging agent cisplatin and the PARP-inhibitor talazoparib thus emerges as a potential new treatment option for pediatric osteosarcoma which will now have to be tested in preclinical primary patient derived in vivo models and clinical studies. 相似文献